Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.

@article{Wang2016QTWiSTAO,
  title={Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.},
  author={Jianmin Wang and Guy Hechmati and Jun Dong and Gregory A. Maglinte and Beth Louise Barber and J Y Douillard},
  journal={Current medical research and opinion},
  year={2016},
  volume={32 3},
  pages={459-65}
}
INTRODUCTION Panitumumab plus infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) significantly improved overall survival versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (mCRC). We applied a quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis to provide an integrated measure of clinical benefit, with the objective of comparing quality-adjusted survival between the two arms. We acknowledge that there… CONTINUE READING